BioCentury
ARTICLE | Financial News

NEA, Versant back ophthalmic play Oyster Point with $22M A round

November 10, 2017 9:30 PM UTC

On Nov. 7, ophthalmic play Oyster Point Pharmaceuticals Inc. (San Francisco, Calif.) raised $22 million in a series A round led by New Enterprise Associates and Versant Ventures. Oyster Point President and CEO Jeffrey Nau told BioCentury he expects the funding to take the company’s two lead candidates through Phase II testing.

Nau said he expects the first candidate to enter the clinic next quarter and the second in 2Q18...

BCIQ Company Profiles

Oyster Point Pharma Inc.